TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial to Compare the Safety, Tolerability, Immunogenicity and Efficacy of One Dose and Two Doses of a Liquid Formulation of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (CAIV-T) Compared With Placebo in Healthy Children
Brief Summary: The purpose of this study is to determine the efficacy of the liquid formulation of CAIV-T against culture confirmed influenza illness in healthy children aged at least 6 months and less than 36 months.


Options:
A: Arm Label: Q/LAIV (MEDI3250); Type: EXPERIMENTAL; Interventions: Biological: Q/LAIV (MEDI3250) | Arm Label: FluMist/B/Yamagata; Type: ACTIVE_COMPARATOR; Interventions: Biological: FluMist/B/Yamagata | Arm Label: FluMist/B/Victoria; Type: ACTIVE_COMPARATOR; Interventions: Biological: FluMist/B/Victoria | Intervention Type: BIOLOGICAL; Name: Q/LAIV (MEDI3250); Assigned to Arm(s): Q/LAIV (MEDI3250) | Intervention Type: BIOLOGICAL; Name: FluMist/B/Yamagata; Assigned to Arm(s): FluMist/B/Yamagata | Intervention Type: BIOLOGICAL; Name: FluMist/B/Victoria; Assigned to Arm(s): FluMist/B/Victoria
B: Arm Label: A/H1N1 Vaccine Group 1; Type: EXPERIMENTAL; Interventions: Biological: Monovalent Subvirion A/H1N1 Influenza vaccine | Arm Label: A/H1N1 Vaccine Group 2; Type: EXPERIMENTAL; Interventions: Biological: Monovalent Subvirion A/H1N1 Influenza vaccine | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Normal saline solution (placebo) | Intervention Type: BIOLOGICAL; Name: Monovalent Subvirion A/H1N1 Influenza vaccine; Assigned to Arm(s): A/H1N1 Vaccine Group 1 | Intervention Type: BIOLOGICAL; Name: Monovalent Subvirion A/H1N1 Influenza vaccine; Assigned to Arm(s): A/H1N1 Vaccine Group 2 | Intervention Type: BIOLOGICAL; Name: Normal saline solution (placebo); Assigned to Arm(s): Placebo Group
C: Intervention Type: BIOLOGICAL; Name: CAIV-T; Assigned to Arm(s): N/A
D: Arm Label: Vaccine; Type: EXPERIMENTAL; Interventions: Biological: SIIL Live Attenuated Influenza Vaccine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: SIIL Live Attenuated Influenza Vaccine; Assigned to Arm(s): Vaccine | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Food Incentives for TB Treatment Compliance in East Timor
Brief Summary: This study will examine whether food is a cost-effective method for improving treatment compliance for TB patients in Timor Leste. Our hypothesis is that the provision of locally available, locally acceptable, cheap and highly nutritious food at the clinic will encourage patients to come for daily directly observed treatment, and thus improve the chance of TB cure and decrease the chance of the development of TB drug resistance. Primary outcome will be successful completion of treatment and secondary outcomes will include treatment compliance and clinical and biological measures of nutritional improvement.


Options:
A: Arm Label: Adherence counseling; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Adherence counseling | Arm Label: Alarm device; Type: ACTIVE_COMPARATOR; Interventions: Device: Alarm device | Arm Label: Counseling and alarm; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Adherence counseling, Device: Alarm device | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Adherence counseling; Assigned to Arm(s): Adherence counseling, Counseling and alarm | Intervention Type: DEVICE; Name: Alarm device; Assigned to Arm(s): Alarm device, Counseling and alarm
B: Intervention Type: BEHAVIORAL; Name: food; Assigned to Arm(s): N/A
C: Intervention Type: BEHAVIORAL; Name: Shared-Decision Making; Assigned to Arm(s): N/A
D: Arm Label: 1 Usual Care Group/Control; Type: OTHER; Interventions: Behavioral: Financial Incentive and Med-eMonitor | Arm Label: 2Med-eMonitor/Reminder; Type: EXPERIMENTAL; Interventions: Device: 2Med-eMonitor | Arm Label: 3 Incentive Group/Lottery; Type: EXPERIMENTAL; Interventions: Behavioral: Financial Incentive and Med-eMonitor | Arm Label: 4 Combined Group/Lottery and Reminder; Type: EXPERIMENTAL; Interventions: Behavioral: Financial Incentive and Med-eMonitor | Intervention Type: BEHAVIORAL; Name: Financial Incentive and Med-eMonitor; Assigned to Arm(s): 1 Usual Care Group/Control, 3 Incentive Group/Lottery, 4 Combined Group/Lottery and Reminder | Intervention Type: DEVICE; Name: 2Med-eMonitor; Assigned to Arm(s): 2Med-eMonitor/Reminder

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Relapse Prevention Trial in Top End Aboriginal People With Chronic Mental Illness
Brief Summary: A new treatment for indigenous people with mental illness in remote communities has been developed. The study hypothesis is that this new treatment will result in better outcomes for clients and carers than the outcomes of clients and carers who do not receive the treatment. The treatment is a combination of a talking treatment and sharing of stories about mental health. The treatment will be delivered to the client with their chosen carer and with the local Aboriginal Mental Health Worker or Health Worker. The treatment will be given by the research team - a psychiatrist and an indigenous research officer. The trial will compare two groups of clients - a control group which is receiving 'treatment as usual', and the group which receives the new treatment. Measures of social functioning and symptoms of mental illness will be administered at base line and every six months for two years.


Options:
A: Arm Label: CapOpus; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive behavioral therapy with motivational interviewing, Behavioral: Non-manualized standard treatment | Arm Label: Treatment as usual; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Non-manualized standard treatment | Intervention Type: BEHAVIORAL; Name: Cognitive behavioral therapy with motivational interviewing; Assigned to Arm(s): CapOpus | Intervention Type: BEHAVIORAL; Name: Non-manualized standard treatment; Assigned to Arm(s): CapOpus, Treatment as usual
B: Arm Label: motivational interviewing; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational Interviewing, Other: Treatment as usual | Arm Label: control group; Type: OTHER; Interventions: Other: Treatment as usual | Intervention Type: BEHAVIORAL; Name: Motivational Interviewing; Assigned to Arm(s): motivational interviewing | Intervention Type: OTHER; Name: Treatment as usual; Assigned to Arm(s): control group, motivational interviewing
C: Intervention Type: BEHAVIORAL; Name: Motivational Interview with care plan and education; Assigned to Arm(s): N/A
D: Arm Label: Experimental group; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive-behavioral therapy program to first-episode psychosis patients and cannabis abuse | Arm Label: Control group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Psychoeducation | Intervention Type: BEHAVIORAL; Name: Cognitive-behavioral therapy program to first-episode psychosis patients and cannabis abuse; Assigned to Arm(s): Experimental group | Intervention Type: BEHAVIORAL; Name: Psychoeducation; Assigned to Arm(s): Control group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Relapse Prevention Trial in Top End Aboriginal People With Chronic Mental Illness
Brief Summary: A new treatment for indigenous people with mental illness in remote communities has been developed. The study hypothesis is that this new treatment will result in better outcomes for clients and carers than the outcomes of clients and carers who do not receive the treatment. The treatment is a combination of a talking treatment and sharing of stories about mental health. The treatment will be delivered to the client with their chosen carer and with the local Aboriginal Mental Health Worker or Health Worker. The treatment will be given by the research team - a psychiatrist and an indigenous research officer. The trial will compare two groups of clients - a control group which is receiving 'treatment as usual', and the group which receives the new treatment. Measures of social functioning and symptoms of mental illness will be administered at base line and every six months for two years.


Options:
A: Arm Label: Cannabis users; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise | Arm Label: Cannabis no-users; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Cannabis no-users, Cannabis users
B: Arm Label: Computerized Brief Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Computerized brief intervention | Arm Label: Counselor delivered brief intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Counselor delivered brief intervention | Intervention Type: BEHAVIORAL; Name: Computerized brief intervention; Assigned to Arm(s): Computerized Brief Intervention | Intervention Type: BEHAVIORAL; Name: Counselor delivered brief intervention; Assigned to Arm(s): Counselor delivered brief intervention
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive-behavioral treatment | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Cognitive-behavioral treatment; Assigned to Arm(s): 1
D: Intervention Type: BEHAVIORAL; Name: Motivational Interview with care plan and education; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Relapse Prevention Trial in Top End Aboriginal People With Chronic Mental Illness
Brief Summary: A new treatment for indigenous people with mental illness in remote communities has been developed. The study hypothesis is that this new treatment will result in better outcomes for clients and carers than the outcomes of clients and carers who do not receive the treatment. The treatment is a combination of a talking treatment and sharing of stories about mental health. The treatment will be delivered to the client with their chosen carer and with the local Aboriginal Mental Health Worker or Health Worker. The treatment will be given by the research team - a psychiatrist and an indigenous research officer. The trial will compare two groups of clients - a control group which is receiving 'treatment as usual', and the group which receives the new treatment. Measures of social functioning and symptoms of mental illness will be administered at base line and every six months for two years.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Expanded Chronic Care Model | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Expanded Chronic Care Model; Assigned to Arm(s): 1
B: Intervention Type: BEHAVIORAL; Name: Motivational Interview with care plan and education; Assigned to Arm(s): N/A
C: Arm Label: Use of a Patient Navigator; Type: EXPERIMENTAL; Interventions: Other: Patient navigation | Arm Label: Usual Care; Type: OTHER; Interventions: Other: Usual care | Intervention Type: OTHER; Name: Patient navigation; Assigned to Arm(s): Use of a Patient Navigator | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): Usual Care
D: Intervention Type: BEHAVIORAL; Name: health education; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Drug Elution and DIstal Protection During Percutaneous CoronAry Intervention in sT Elevation Myocardial InfarctiON. Acronym: Dedication
Brief Summary: The purpose of this study is to evaluate the clinical, echocardiographic and angiographic outcome of distal protection in the infarct related coronary artery and implantation of drug eluting versus bare metal stents in patients with ST-elevation myocardial infarctions treated acutely with percutaneous coronary intervention.


Options:
A: Arm Label: Drug Eluting Absorbable Metal Scaffold; Type: EXPERIMENTAL; Interventions: Device: Percutaneous Coronary Intervention (DREAMS) stenting | Intervention Type: DEVICE; Name: Percutaneous Coronary Intervention (DREAMS) stenting; Assigned to Arm(s): Drug Eluting Absorbable Metal Scaffold
B: Intervention Type: PROCEDURE; Name: Distal protection and drug eluting stent; Assigned to Arm(s): N/A
C: Arm Label: bare metal stent; Type: ACTIVE_COMPARATOR; Interventions: Device: Bare metal stent implantation | Arm Label: Endeavor sprint stent; Type: EXPERIMENTAL; Interventions: Device: zotarolimus eluting stent | Intervention Type: DEVICE; Name: Bare metal stent implantation; Assigned to Arm(s): bare metal stent | Intervention Type: DEVICE; Name: zotarolimus eluting stent; Assigned to Arm(s): Endeavor sprint stent
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: abciximab followed by implantation of bare metal stent | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Other: abciximab and Sirolimus eluting stent | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Other: tirofiban and bare metal stent | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Other: tirofiban and sirolimus-eluting stent | Intervention Type: OTHER; Name: abciximab followed by implantation of bare metal stent; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: abciximab and Sirolimus eluting stent; Assigned to Arm(s): 2 | Intervention Type: OTHER; Name: tirofiban and bare metal stent; Assigned to Arm(s): 3 | Intervention Type: OTHER; Name: tirofiban and sirolimus-eluting stent; Assigned to Arm(s): 4

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Trial To Assess The Impact Of Loco-Regional Treatment On Survival Of Patients With Metastatic Breast Cancer At First Presentation
Brief Summary: Traditionally metastatic breast cancer patients are not offered loco-regional treatment except in cases of fungation or bleeding. However, scientific evidence for such omission of loco-regional treatment in metastatic breast cancer patients is lacking. On one hand, studies have shown that removal of primary tumor at times leads to complete disappearance of metastases and improvement in survival in renal cell carcinoma patients. However, such studies have never been performed in other solid tumors. On the other hand, there is a strong body of evidence in experimental settings that show that removal of primary tumor allows growth of metastasis. There is lack of similar data in humans in clinical settings. Offering loco-regional treatment in metastatic breast cancer patients in a setting of randomized controlled trial will help in improving survival of such patients and understanding the natural history of breast cancer.


Options:
A: Arm Label: Loco Regional Treatment Arm (LRT); Type: EXPERIMENTAL; Interventions: Procedure: Surgery for breast cancer | Arm Label: No Loco-regional Treatment Arm; Type: ACTIVE_COMPARATOR; Interventions: Other: No Loco-regional treatment | Intervention Type: PROCEDURE; Name: Surgery for breast cancer; Assigned to Arm(s): Loco Regional Treatment Arm (LRT) | Intervention Type: OTHER; Name: No Loco-regional treatment; Assigned to Arm(s): No Loco-regional Treatment Arm
B: Arm Label: Upfront surgery; Type: EXPERIMENTAL; Interventions: Procedure: upfront breast surgery | Arm Label: Systemic therapy; Type: OTHER; Interventions: Other: systemic therapy | Intervention Type: PROCEDURE; Name: upfront breast surgery; Assigned to Arm(s): Upfront surgery | Intervention Type: OTHER; Name: systemic therapy; Assigned to Arm(s): Systemic therapy
C: Arm Label: Pertuzumab + Trastuzumab + Docetaxel; Type: EXPERIMENTAL; Interventions: Drug: Pertuzumab, Drug: Trastuzumab, Drug: Docetaxel | Arm Label: Placebo + Trastuzumab + Docetaxel; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Trastuzumab, Drug: Docetaxel | Intervention Type: DRUG; Name: Pertuzumab; Assigned to Arm(s): Pertuzumab + Trastuzumab + Docetaxel | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + Trastuzumab + Docetaxel | Intervention Type: DRUG; Name: Trastuzumab; Assigned to Arm(s): Pertuzumab + Trastuzumab + Docetaxel, Placebo + Trastuzumab + Docetaxel | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): Pertuzumab + Trastuzumab + Docetaxel, Placebo + Trastuzumab + Docetaxel
D: Arm Label: A; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: B; Type: OTHER; Interventions: Procedure: Primary surgery | Intervention Type: PROCEDURE; Name: Primary surgery; Assigned to Arm(s): B

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Do Nasogastric Tubes After Cardiac Surgery Reduce Nausea and Vomiting. A Prospective Randomized Clinical Trial.
Brief Summary: Gastric emptying is delayed after cardiac surgery, but the efficacy of the nasogastric (NG) tube in preventing distension and reducing vomiting is unclear. Nasogastric (NG) tubes are routinely used in patients undergoing surgery. They are presumed to reduce postoperative nausea and vomiting (PONV) and to lessen the risk of aspiration by reducing residual gastric volumes; however, their insertion and use is not however without potentially serious complications. Existing literature does not address their efficacy in reducing PONV after cardiac surgery. However, current evidence suggests that up to 50% of patients in this group suffer significant nausea and vomiting. The objective of this study is to determine whether NG tubes should continue to be inserted routinely during cardiac surgery to reduce PONV.


Options:
A: Intervention Type: DRUG; Name: Red blood cell transfusion; Assigned to Arm(s): N/A
B: Arm Label: Liberal; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Liberal transfusion strategy | Arm Label: Restrictive; Type: EXPERIMENTAL; Interventions: Behavioral: Restrictive transfusion strategy | Intervention Type: BEHAVIORAL; Name: Liberal transfusion strategy; Assigned to Arm(s): Liberal | Intervention Type: BEHAVIORAL; Name: Restrictive transfusion strategy; Assigned to Arm(s): Restrictive
C: Arm Label: Restrictive Transfusion Strategy; Type: ACTIVE_COMPARATOR; Interventions: Other: Restrictive Transfusion Strategy | Arm Label: Liberal Transfusion Strategy; Type: ACTIVE_COMPARATOR; Interventions: Other: Liberal transfusion strategy | Intervention Type: OTHER; Name: Restrictive Transfusion Strategy; Assigned to Arm(s): Restrictive Transfusion Strategy | Intervention Type: OTHER; Name: Liberal transfusion strategy; Assigned to Arm(s): Liberal Transfusion Strategy
D: Intervention Type: DEVICE; Name: Placement of nasogastric tube; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double Blind Comparison of Lithium Monotherapy Versus Lithium Plus Divalproex for the Outpatient Management of Hypomania/Mania in Patients With Rapid Cycling Bipolar Disorder Comorbid With Substance Abuse/Dependence
Brief Summary: This study will determine the efficacy and safety of combination therapy with divalproex and lithium for treating mania in people with rapid cycling bipolar disorder and a substance abuse disorder.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: vigabatrin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: vigabatrin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2
B: Arm Label: Lithium plus Divalproex; Type: EXPERIMENTAL; Interventions: Drug: Lithium, Drug: Divalproex | Arm Label: Lithium plus placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Lithium, Drug: Placebo | Intervention Type: DRUG; Name: Lithium; Assigned to Arm(s): Lithium plus Divalproex, Lithium plus placebo | Intervention Type: DRUG; Name: Divalproex; Assigned to Arm(s): Lithium plus Divalproex | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Lithium plus placebo
C: Arm Label: Topiramate; Type: EXPERIMENTAL; Interventions: Drug: Topiramate + Cognitive Behavioral Therapy | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo + Cognitive Behavioral Therapy | Intervention Type: DRUG; Name: Topiramate + Cognitive Behavioral Therapy; Assigned to Arm(s): Topiramate | Intervention Type: DRUG; Name: Placebo + Cognitive Behavioral Therapy; Assigned to Arm(s): Placebo
D: Arm Label: 1 topiramate + CR; Type: EXPERIMENTAL; Interventions: Drug: topiramate, Behavioral: Contingency Reinforcement | Arm Label: 2 topiramate + NonCR; Type: EXPERIMENTAL; Interventions: Drug: topiramate | Arm Label: 4 Placebo + NonCR; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo + NonCR | Arm Label: 3 Placebo + CR; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Contingency Reinforcement | Intervention Type: DRUG; Name: topiramate; Assigned to Arm(s): 1 topiramate + CR, 2 topiramate + NonCR | Intervention Type: BEHAVIORAL; Name: Contingency Reinforcement; Assigned to Arm(s): 1 topiramate + CR, 3 Placebo + CR | Intervention Type: DRUG; Name: placebo + NonCR; Assigned to Arm(s): 4 Placebo + NonCR

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The PAL Trial (Physical Activity and Lymphedema)
Brief Summary: The purpose of the PAL trial is to increase the understanding of the experiences of long-term breast cancer survivors.

Study hypothesis: Strength training will not increase the rate of lymphedema or worsen lymphedema as compared to the non-exercising control participants.


Options:
A: Intervention Type: BEHAVIORAL; Name: Strength training; Assigned to Arm(s): N/A
B: Arm Label: Exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise | Arm Label: Control; Type: NO_INTERVENTION; Interventions: Behavioral: Control | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Exercise | Intervention Type: BEHAVIORAL; Name: Control; Assigned to Arm(s): Control
C: Arm Label: 1: exercise with 2 counseling types; Type: EXPERIMENTAL; Interventions: Behavioral: Experimental 1: exercise with 2 counseling types | Arm Label: 2. Usual Care - written materials; Type: OTHER; Interventions: Other: Usual Care - written materials | Intervention Type: BEHAVIORAL; Name: Experimental 1: exercise with 2 counseling types; Assigned to Arm(s): 1: exercise with 2 counseling types | Intervention Type: OTHER; Name: Usual Care - written materials; Assigned to Arm(s): 2. Usual Care - written materials
D: Arm Label: Lifestyle counseling; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: behavioral dietary intervention, Other: counseling intervention, Other: educational intervention, Other: preventative dietary intervention, Procedure: quality-of-life assessment | Arm Label: Without Counseling; Type: ACTIVE_COMPARATOR; Interventions: Procedure: quality-of-life assessment | Intervention Type: BEHAVIORAL; Name: behavioral dietary intervention; Assigned to Arm(s): Lifestyle counseling | Intervention Type: OTHER; Name: counseling intervention; Assigned to Arm(s): Lifestyle counseling | Intervention Type: OTHER; Name: educational intervention; Assigned to Arm(s): Lifestyle counseling | Intervention Type: OTHER; Name: preventative dietary intervention; Assigned to Arm(s): Lifestyle counseling | Intervention Type: PROCEDURE; Name: quality-of-life assessment; Assigned to Arm(s): Lifestyle counseling, Without Counseling

Answer: A